Exane Derivatives Nektar Therapeutics Transaction History

Exane Derivatives

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Jul 10, 2020	SELL	$16.86 - $23.44 $48,017 - $66,757	-2,848 Closed	0 $0
Q1 2020 Apr 17, 2020	SELL	$14.47 - $27.96 $162,729 - $314,438	-11,246 Reduced 79.79%	2,848 $50,000
Q4 2019 Jan 22, 2020	SELL	$15.87 - $23.12 $253,253 - $368,948	-15,958 Reduced 53.1%	14,094 $304,000
Q3 2019 Oct 15, 2019	BUY	$16.91 - $36.27 $226,594 - $486,018	13,400 Added 80.47%	30,052 $547,000
Q2 2019 Jul 12, 2019	SELL	$31.0 - $36.3 $143,530 - $168,069	-4,630 Reduced 21.76%	16,652 $0
Q1 2019 Apr 24, 2019	BUY	$31.58 - $46.35 $672,085 - $986,420	21,282 New	21,282 $0

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.